Novo Nordisk Forges Ahead with Oral Wegovy and Weekly Insulin Amid CagriSema Device Study Withdrawals

Novo Nordisk launches oral Wegovy in 70,000 US pharmacies and once-weekly insulin Awiqli in India, while quietly withdrawing CagriSema device studies. Stock edges higher.

Novo Nordisk is executing a multi-front strategy to defend its dominance in the obesity and diabetes markets, rolling out an oral version of Wegovy across the United States and launching the world's first once-weekly basal insulin in India, all while quietly eliminating a pair of clinical studies tied to the delivery mechanism of its next-generation candidate, CagriSema. Investors have taken the mixed signals in stride: the stock closed at €43.30 on Friday, up 0.99 percent, and by mid-week traded at €42.98, modestly higher by 0.24 percent.

The two withdrawn studies, both filed on January 21, 2026, and marked as "withdrawn" on July 7, 2026, were designed to compare different injection versions of CagriSema — one in overweight patients, the other in people with type 2 diabetes. The decision affects only the device strategy, not the drug compound itself. Novo Nordisk had previously terminated a related single-chamber co-formulation project for CagriSema. CEO Mike Doustdar attributed that earlier move to "portfolio considerations" while reaffirming that the overall launch timeline remains unchanged: a U.S. approval is still expected in the fourth quarter of 2026, with commercial rollout slated for early 2027.

The commercial front, meanwhile, is buzzing. Oral Wegovy tablets, which clinical data show deliver roughly 17 percent weight loss with daily dosing, began appearing this week in more than 70,000 U.S. pharmacies, including CVS and Costco. Novo Nordisk has introduced a tiered pricing structure to blunt Eli Lilly's competitive pressure. The entry-level 1.5-mg dose costs about $5 per day, or roughly $149 a month. The 4-mg dose is priced at $149 through April 15, then rises to $199, while the highest strength will eventually cost $299 monthly. Patients with private insurance may pay as little as $25 out of pocket.

The impact of expanded coverage under Medicare is already visible. Since the FDA approved Wegovy for cardiovascular risk reduction in March 2024, prescriptions filled under Medicare Part D surged 598 percent in six months. Total prescriptions climbed from roughly 367,000 to over 868,000 — a 136.4 percent increase. Yet less than 1 percent of the 3.6 million eligible Medicare beneficiaries have actually picked up the drug, according to the USC Schaeffer Center. High copays and cautious insurer plan designs continue to dampen uptake. A pilot program called "Medicare GLP-1 Bridge" aims to address the gap, but it is set to expire in 2027.

Across the Atlantic, Novo Nordisk launched Awiqli in India on July 10 — the first insulin anywhere that requires just one weekly injection. For patients accustomed to daily shots, that means a reduction from 365 to 52 injections per year. India is home to roughly 101 million diabetes patients, making it a massive addressable market. The weekly cost is about 261 rupees. Data from the ONWARDS trial series, which enrolled more than 4,000 adults, showed better HbA1c reductions compared with daily insulin glargine.

Backing up the pipeline and commercial push, Novo Nordisk has been steadily buying back shares. Since February 4, 2026, the company has repurchased more than 23 million B-shares at an average price of 270.32 Danish kroner, translating to a total transaction volume of over €830 million. The buyback has helped underpin the stock's recovery from its 2026 low of €30.25 on March 2. Since that trough, shares have climbed about 43 percent. The 30-day gain stood at 16.71 percent in early July and had edged slightly lower to 15.85 percent by mid-month. The stock still trades roughly 29-30 percent below its record high of €61.20 from July 2025.

Analyst sentiment has turned cautiously more supportive. HSBC raised its price target from 280 to 300 Danish kroner but maintained a "Hold" rating. Danske Bank is more bullish, setting a target of 365 kroner with a "Buy" recommendation. Market observers view the CagriSema device study withdrawals as a sideshow rather than a threat to the core business. The real battleground remains the GLP-1 market, where Eli Lilly's tirzepatide franchise continues to apply pressure. The stock's 50-day moving average of €39.51 now sits nearly 10 percent below the current price, signaling a firm short-term uptrend. With a relative strength index of 64.4, the stock is approaching overbought territory, while annualized volatility hovers around 30 percent.

Novo Nordisk's CEO insists the company is on track. Beyond CagriSema, the pipeline includes the early-stage candidate Zenagamtide, and analysts expect the obesity market to remain a duopoly between Novo Nordisk and Eli Lilly well into the 2030s. Acquisitions may further reinforce that position. For now, the simultaneous rollouts of oral Wegovy in the U.S. and weekly insulin in India give investors tangible proof of execution, even as a small but symbolic pipeline adjustment reminds them that not every experimental path survives scrutiny.